Maryland-based independent licensees of the Blue Cross Blue Shield Association have filed a lawsuit against pharmaceutical giant Amgen Inc. and its subsidiaries. The plaintiffs allege that Amgen has engaged in unlawful monopolistic practices aimed at inflating the cost of the blockbuster drug Enbrel. These practices, according to the suit, have significantly driven up healthcare expenses related to the autoimmune medication.
The case raises critical questions about the balance between competition and innovation within the pharmaceutical industry. Amgen, known for its significant market presence, is accused of leveraging its market power in a manner that stifles competition and maintains high drug prices.
Further details and developments from this legal dispute can be found in the Law360 article.